In a press launch in late September saying that Eisai’s experimental Alzheimer’s drug had considerably slowed development of the memory-robbing illness, the corporate’s chief government officer, Haruo Naito, was something however circumspect. The outcomes from the late-stage research, he stated, “show the amyloid speculation.”
